• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Stocks

Biogen and Lilly: How I'm Playing the Alzheimer's Drug Stocks Game

Let's size up the prospects for treatments and the shares.
By STEPHEN GUILFOYLE
Sep 28, 2022 | 10:17 AM EDT
Stocks quotes in this article: BIIB, ESALY, LLY, RHHBY

Eureka!?!
 
Cambridge, Massachusetts-based biotech Biogen ( BIIB) and Japanese drug maker Eisai ( ESALY) reported on Wednesday morning that their experimental Alzheimer's disease treatment had met the main goal of a late-stage clinical trial. The candidate, Lecanemab, reduced the pace of cognitive decline in patients diagnosed with early-stage disease by 27% over 18 months compared to those treated with a placebo.
 
This result could be a major accomplishment for researchers who have been trying for decades to find a way to treat Alzheimer's. The medicine, before Biogen and Eisai started trying to develop it, was licensed from Sweden's BioArctic.
 
All three stocks were up in their home markets on the news. In fact, the stocks of both Eli Lilly ( LLY) and Roche Holding ( RHHBY) were also higher in early trading as they are also known to be working on similar Alzheimer's treatments. I am long LLY stock.
 
Just an FYI: There were some negative side effects experienced during the Lecanemab trial. Some patients did have to deal with brain swelling and/or bleeding. Severe cases were said to be rare, though.

Background on Lecanemab and Amyloid

Lecanemab is meant to reduce or remove a toxic protein known as amyloid that clutters the brain and is thought by many to be a leading cause of Alzheimer's disease. Many drugs have been tested with less-than-spectacular results over the years that attack amyloid. The concept that amyloid is a primary cause of the disease and that by removing or reducing that protein in a patient's brain would improve that patient's condition is known as the "amyloid hypothesis."
 
This is not the first at-bat for Biogen and Eisai in trying to develop an amyloid-reducing medication. Readers may recall in mid-2021, the drug Aduhelm, in one trial, mildly slowed cognitive decline in Alzheimer's patients but failed to show an effect in another trial. Aduhelm was controversially approved in the U.S., but failed commercially because Medicare refused to pay for it, not just because of the price tag, but because of the contradictory trial results.
 
These results if not proving the amyloid hypothesis, at least lend some credibility to the idea.

Prospects

Lon Schneider, professor of Psychiatry and Behavioral Sciences at the University of Southern California, was quoted at Bloomberg News. Schneider indicated that he thought Lecanemab would probably receive full FDA approval based on these clinical results.
 
He sounded less than thrilled with the 27% slowing in the pace of cognitive decline, however: "The debate is going to be about the small effect size." Schneider is not sure that 27% over 18 months will be seen as clinically meaningful.

Biogen & Lilly

Though highly profitable, Biogen stock has been in decline as have the company's earnings and revenues on a year-over-year basis. Despite beating Wall Street expectations for both top-line and bottom-line performance for the June quarter, Biogen has suffered negative earnings growth in five of the past six quarters and negative revenue growth for eight consecutive quarters.
 
The company still drove solid free cash flow, and still runs with a solid balance sheet. Yet coming into this news, the stock was trading at just 12 times 12-month forward-looking earnings.
 
With the shares up close to 50% in premarket trading and still more than 35% after the open Wednesday, that could quickly become 18 times, even before factoring in when (and if) Lecanemab might contribute to the company's financial performance.
 
The stock is trading around $271 at around 10:00 a.m.
 
 
Readers can see that BIIB has not traded in this neighborhood since 2021.
 
 
BIIB has traded in a basing range of consolidation for literally all of 2022. The gap created Wednesday morning will be enormous and it would not surprise me in the least if it fills at least partially if not today than some "down" day for the market soon. At last glance, less than 1.5% of the float was held in short positions, so you are not going to see a squeeze. My bet would be bearish at anything approaching $300.
 
However, I told you that I was long Eli Lilly.
 
In my opinion, Lilly has more going for it. Lilly also has a strong balance sheet and strong free cash flow. Lilly seems to have better luck growing both revenues and earnings. The company also has the Mounjaro diabetes drug, which appears to successfully combat obesity. I will await results from the Eli Lilly anti-amyloid anti-Alzheimer's disease offering.
 
 
In the chart, above, readers can see LLY coming to an inflection point as the above pennant formation closes. The stock could go either way in a hurry as that happens.
 
I know that the 200-day simple moving average (SMA) is just as rapidly rising about $25 below where the stock is. I see this as supportive as this is something that portfolio managers look for when deciding on whether they should increase or decrease exposure.
 
My primary target here is the $335 July high, but I see that spot as more of a pivot.
 
Should LLY take and hold $335, which is possible as soon as today, my target moves to $385.
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Guilfoyle was long LLY equity.

TAGS: Fundamental Analysis | Investing | Markets | Stocks | Trading | Biotechnology | U.S. Equity

More from Stocks

You Don't Have to Trade All at Once

James "Rev Shark" DePorre
Sep 23, 2023 10:00 AM EDT

Trading in multiple time frames not only reduces risks, but also provides strategic flexibility. Let me show you what I mean and how to do it.

FS Insight Weekly Roadmap: Market Response to Hawkish Fed Is an Overreaction

Tom Lee and the FSI Team
Sep 23, 2023 9:10 AM EDT

Here's why we believe 'higher for longer DUE to higher GDP' has a more dovish tone, and remain constructive for the rest of the year.

This Dividend Aristocrat Has All the Raw Materials to Make It a Top Pick

Bob Ciura
Sep 23, 2023 7:30 AM EDT

This name has been down, but now I think it's charged up to cruise into the year's end.

The Bears Just Moved Into Wall Street

James "Rev Shark" DePorre
Sep 22, 2023 4:26 PM EDT

Technically, the bears are in control of this market now.

Don't Be a Sap and Step Into a Value Trap

Bret Jensen
Sep 22, 2023 12:30 PM EDT

There are plenty of stocks that look like value plays but aren't as the market continues to drag more share prices down.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 12:20 PM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Trading in Multiple Time Frames
  • 10:24 AM EDT BRUCE KAMICH

    This Could Get Messy

    A number of key stocks are getting close to import...
  • 01:41 PM EDT CHRIS VERSACE

    Latest AAP Podcast With Helene Meisler!

    Listen in as the Action Alerts PLUS podcast talks ...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login